Shoulder pain in a patient with renal cell carcinoma? Suprascapular neuropathy caused by bone metastasis of renal cell carcinoma: A case report

2021 ◽  
Vol 35 (8) ◽  
pp. 1629-1633
Author(s):  
Jeong-Se Noh ◽  
Dong Hyun Kim ◽  
Seong-Min Chun ◽  
Yoon-Hee Choi

Background: Pain management is crucial in palliative care for patients with advanced cancer. Here, we report a case of shoulder pain in a patient with renal cell carcinoma. Case presentation: A 36-year-old male diagnosed metastatic renal cell carcinoma presented with pain and weakness on left shoulder for more than 6 months. Physical examination showed limited range of motion and atrophic changes on supraspinatus and infraspinatus muscles. Weakness in shoulder abduction and external rotation was also noted. Possible courses of action: In this case, suprascapular neuropathy, adhesive capsulitis of shoulder and metastatic lesions involving shoulder joint were suspected. Formulation of a plan: We planned imaging studies including X-ray, bone scan, magnetic resonance imaging, and electrodiagnostic studies. Outcome: Imaging and electrodiagnostic studies showed suprascapular neuropathy by bone metastasis. Conservative treatment including injection and rehabilitation therapy reduced the patient’s pain and improved the range of motion limitation. Lessons from the case: Clinicians should be aware that bone metastasis in patients with advanced cancer can cause suprascapular neuropathy, shoulder pain and shoulder dysfunction. View on research problems, objectives, or questions generated by the case: More research is expected on development of an early surveillance model, barriers to cancer pain management, communication from patients’ perspectives.

2014 ◽  
Vol 35 (12) ◽  
pp. 1247-1253 ◽  
Author(s):  
Punit Sharma ◽  
Sellam Karunanithi ◽  
Partha S. Chakraborty ◽  
Rajeev Kumar ◽  
Amlesh Seth ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (18) ◽  
pp. 26879-26887 ◽  
Author(s):  
Xiaolin Lu ◽  
Weijie Gu ◽  
Hailiang Zhang ◽  
Yao Zhu ◽  
Guohai Shi ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (10) ◽  
pp. 17012-17026 ◽  
Author(s):  
Jiang Wang ◽  
Hongbo You ◽  
Jun Qi ◽  
Caihong Yang ◽  
Ye Ren ◽  
...  

2014 ◽  
Vol 13 (1) ◽  
pp. e188
Author(s):  
M.P. Valta ◽  
H. Zhao ◽  
A. Ingels ◽  
A.E. Thong ◽  
R. Nolley ◽  
...  

1988 ◽  
Vol 6 (5) ◽  
pp. 839-853 ◽  
Author(s):  
S L Topalian ◽  
D Solomon ◽  
F P Avis ◽  
A E Chang ◽  
D L Freerksen ◽  
...  

Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with advanced cancer have yielded encouraging results. We have thus sought ways to enhance the effectiveness of adoptive immunotherapy while minimizing its toxic side effects. Murine experiments have identified tumor-infiltrating lymphocytes (TIL) as killer cells more effective than LAK cells and less dependent on adjunctive systemically administered IL-2 to mediate antitumor effects. Accordingly, we performed a pilot protocol to investigate the feasibility and practicality of administering IL-2-expanded TIL to humans with metastatic cancers. Twelve patients, including six with melanoma, four with renal cell carcinoma, one with breast carcinoma, and one with colon carcinoma, were treated with varying doses and combinations of TIL (8.0 X 10(9) to 2.3 X 10(11) cells per patient), IL-2 (10,000 to 100,000 U/kg three times daily to dose-limiting toxicity), and cyclophosphamide (CPM) (up to 50 mg/kg). Two partial responses (PR) to therapy were observed: pulmonary and mediastinal masses regressed in a patient with melanoma, and a lymph node mass regressed in a patient with renal cell carcinoma. One additional patient with breast cancer experienced a partial regression of disease in lymph nodal and cutaneous sites with complete elimination of malignant cells from a pleural effusion, although cutaneous disease recurred at 4 weeks. The toxicities of therapy were similar to those ascribed to IL-2; no toxic effects were directly attributable to TIL infusions. In five of six melanoma patients, TIL demonstrated lytic activity specific for the autologous tumor target in short-term chromium-release assays, distinct from the nonspecific lytic activity characteristic of LAK cells. This study represents an initial attempt to identify and use lymphocyte subsets with enhanced tumoricidal capacity in the adoptive immunotherapy of human malignancies.


2019 ◽  
Vol 45 (7) ◽  
pp. 1246-1252 ◽  
Author(s):  
Zixiong Huang ◽  
Yiqing Du ◽  
Xiaopeng Zhang ◽  
Huixin Liu ◽  
Shijun Liu ◽  
...  

2007 ◽  
Vol 26 (3-4) ◽  
pp. 691-704 ◽  
Author(s):  
Kristy Weber ◽  
Michele Doucet ◽  
Scott Kominsky

Sign in / Sign up

Export Citation Format

Share Document